Know Labs Presents Promising Clinical Data on Non-Invasive Glucose Monitoring Technology
核心洞察
Know Labs (搜索) presented clinical study results at the AACE Annual Meeting, demonstrating the accuracy of its non-invasive glucose monitoring sensor.
The study involved individuals with diabetes (搜索) and used venous blood as a reference, employing a machine learning model for data analysis.
Know Labs (搜索) plans to conduct large-scale clinical trials with its KnowU™ wearable CGM to assess performance in real-world conditions and extreme glycemic ranges.
Know Labs (搜索), Inc. (NYSE American: KNW) presented clinical research at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana, showcasing the potential of its non-invasive glucose monitoring technology. The oral abstract presentation, delivered on May 9, 2024, highlighted results from a clinical study demonstrating the accuracy and medical application of Know Labs' proprietary sensor.
The presentation, titled "Efficacy of a Non-Invasive Blood Glucose Monitor for Diabetes (搜索) Management Using a Radiofrequency Sensor and Machine Learning," featured interim results initially announced in March. The study involved individuals with diabetes, utilizing venous blood as a comparative reference. A machine learning model, trained on data collected in a lab setting, was employed to analyze the sensor's performance.
Advancing Towards FDA Clearance
As Know Labs (搜索) progresses towards FDA clearance in 2024, the company plans to deploy its KnowU™ wearable, a non-invasive continuous glucose monitor (CGM), in extensive, external clinical trials. These trials aim to evaluate the technology's performance during continuous wear, in more realistic environments, and across a broader spectrum of glycemic ranges, specifically below 70 mg/dL and above 350 mg/dL. These studies will help refine the device and improve model techniques.
About Know Labs' Technology
Know Labs (搜索)' platform technology utilizes spectroscopy to direct electromagnetic energy through a substance, capturing a unique molecular signature. This technology can be integrated into various form factors, including wearable, mobile, and bench-top devices. The patented and patent-pending technology enables the identification and monitoring of analytes that previously required invasive, expensive, and time-consuming lab-based tests. The initial application focuses on a non-invasive glucose monitor, designed to provide users with accessible and affordable real-time blood glucose level information. The product will require U.S. Food and Drug Administration clearance before market introduction.